Northwest Biotherapeutics Inc. (NWBO)
OTC PINK OTC PINK Primary Summary
Northwest Biotherapeutics Inc. (NWBO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Northwest Biotherapeutics Inc. ever had a stock split?
Northwest Biotherapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ms. Linda F. Powers J.D. CEO | OTC PINK Exchange | 66737P600 CUSIP |
| US Country | 25 Employees | - Last Dividend | 26 Sep 2012 Last Split | - IPO Date |
Overview
Northwest Biotherapeutics, Inc. is a pioneering biotechnology entity, focused on crafting personalized immune therapies for a broad spectrum of cancer types, both within the United States and on an international scale. Since its inception in 1996, it has dedicated itself to the development of innovative treatment methodologies, utilizing its proprietary DCVax technology. This technology harnesses the power of activated dendritic cells to stimulate a patient’s immune system to combat cancer more effectively. The company's commitment to leveraging the body's own defense mechanisms to fight cancer showcases its innovative approach to oncology. Headquartered in Bethesda, Maryland, Northwest Biotherapeutics continues to push the boundaries of cancer immunotherapy through rigorous research and development efforts.
Products and Services
- DCVax-L
As the flagship product of Northwest Biotherapeutics, DCVax-L represents a significant breakthrough in the treatment of Glioblastoma multiforme, a highly aggressive form of brain cancer. Having completed Phase III clinical trials, DCVax-L embodies the forefront of the company's personalized immune therapy arsenal. It operates by utilizing a patient’s dendritic cells, activated and re-introduced into the body to enhance the immune system's ability to recognize and destroy cancer cells, showcasing a novel approach to cancer treatment that goes beyond conventional methodologies.
- DCVax-Direct
Expanding on its suite of innovative cancer therapies, Northwest Biotherapeutics is also developing DCVax-Direct. This product is designed to target inoperable solid tumors, offering hope to patients with challenging cancer diagnoses. Currently in Phase I/II clinical trials, DCVax-Direct employs a direct injection technique to deliver activated dendritic cells into the tumor, aiming to provoke a more potent immune response against cancer cells. This approach demonstrates the company's dedication to leveraging advanced science and technology to provide new solutions for cancer treatment.
